AMAshwini Mathur

Ashwini Mathur

*This is an algorithmically generated author record based on publicly available information.

Ashwini Mathur has a total of 153 co-authors. Here are the top co-authors by number of shared publications:

  • Harry K. Genant

    Osteoporosis and Arthritis Research Group, Department of Radiology, University of California San Francisco, San Francisco, California, USA

    7 shared publications
  • H K Genant

    4 shared publications
  • P Lang

    Department of Radiology, Stanford University Hospital, CA 94305-5105, USA

    4 shared publications
  • Ying Lu

    Department of Radiology, University of California San Francisco, 94143-0628, USA

    4 shared publications
  • Michael Jergas

    Musculoskeletal Section and Osteoporosis Research Group, Department of Radiology, University of California, San Francisco, California, U.S.A.

    3 shared publications
  • Peter Augat

    Institute for Biomechanics, BG Unfallklinik Murnau , Murnau , Germany

    3 shared publications

Latest Publications

  • Open Access

    From Product to Patient: An Integrated Product Profile for Access, Adoption, and Health Impact

    by Ashwini Mathur

    Regulatory approval of a medicine does not ensure that patients can access it. Access depends on 6 decisions: regulatory approval, health technology assessment and reimbursement, guideline placement, policy, health-system delivery, and use by the patient. These decisions are conjunctive, so the probability of access is the product of their probabilities. Six decisions, each with a probability of 0.9, give an overall probability of 0.53. The decisions are separate but not independent. They draw on a common set of development choices, which we call coupled choices: the comparator, the trial population, the endpoint and estimand, the dose, route, and regimen, the care setting and monitoring, and the presentation and supply. A choice that raises one factor can lower another, and none of the functions is charged with the product. Existing frameworks have moved downstream requirements upstream, including Target Product Profiles, Integrated Evidence Plans, the Target Policy Profile, and the World Health Organization Evidence Considerations for Vaccine Policy, but each serves a single decision. We propose the Integrated Product Profile (IPP), a profile of the choices that enter more than one downstream decision, recording what each decision requires of them, how far development can influence them, and when they become fixed. In practice the IPP is short: 6 coupled choices, with 3 entries recorded against each, owned by the team that owns the product profile. We give a worked example for a fictional oral GLP-1 agonist and set out the questions to be tested. The IPP would complement, not replace, existing frameworks.

  • Open Access

    Principled Simulation of Survival Data for Replicating Tree-Structured Survival Analysis

    by Ashwini Mathur

    Simulation studies are routine in biostatistical research, but the design choices that go into building a synthetic dataset are rarely documented in detail. This paper records the full iterative construction of a multivariate survival simulation aimed at replicating the principal findings of Lu, Black, and Genant (2003), in which Tree-Structured Survival Analysis (TSSA) was used to identify hip-fracture risk subgroups in the Study of Osteoporotic Fractures (SOF). I treat the published paper as the only source of truth, derive marginal distributions, effect sizes, and event rates from its tables, and iteratively refine the datagenerating process until the resulting tree reproduces the published structure. The exercise has four arcs. First, a baseline simple-first development (multivariate normal covariates with a Cox-Weibull hazard) is iterated through five steps, surfacing two methodological lessons: marginal hazard ratios cannot be plugged into multivariable simulations without shrinkage, and lopsided published trees imply regime-switching truth. Second, I extend to a Gaussian copula with shifted lognormal marginals, then independently construct a 'naive copula' counterfactual that begins from sophistication without the baseline lessons; the counterfactual fails by every replication target with marginal hazard ratios biased upward by 600–10,000%. Third, I map the design space across six axes (covariate marginals, censoring/competing risks, interaction structure, measurement error, hazard family, sample size) using 200-seed Monte Carlo experiments per axis, finding that the axes cluster into three groups by impact: those that change population partition geometry (large effect on tree behaviour), those that change event timing given the partition (negligible effect), and sample size (which affects estimation precision but not bias). Fourth, I search for an optimal combination across axes, demonstrating that no single configuration matches all published features simultaneously. Three principles emerge from the empirical work. The Diagnostic Isolation Principle: simulations should be built in the order that maximises the modeller's ability to attribute failures to specific components, not in the order that maximises any one component's realism. The Group Hierarchy Principle: treebased survival analyses are sensitive to design axes that determine partition geometry and robust to those that determine event timing. The Non-identifiability Principle: published descriptive statistics under-determine the underlying data-generating process; a simulation can identify a family of compatible mechanisms but not a unique winner. The combination of seventeen multi-seed Monte Carlo experiments provides quantitative empirical support for all three principles.

  • Open Access

    Clinical Research in Ayurveda - Can Statistics as A Scientific Discipline Help the Cause?

    by Vinay Mahajan, Vivek Sanker Mk, Aswhini Mathur

    Ayurveda as a healthcare system has survived for thousands of years but continues to be dogged by reported lack of efficacy of the treatments in clinical trials. The reported lack of efficacy could be due to a real lack of efficacy (which then contradicts the survival of Ayurveda as a functional medical system enjoying considerable public patronage) or could be attributed to inadequacies in the efforts towards evidence generation or in a larger context the overall scientific conduct of research in Ayurveda. In an effort towards better evidence generation, there is an immediate need for standardizing the design, conduct and reporting of clinical trials of Ayurveda but it is a daunting task. For this effort to benefit the scientific endeavors of Ayurveda researchers, it should allow the researchers to be able to apply Ayurveda’s multi-component, individualized and inherently holistic approach. Statistical principles can benefit this effort. Statistical hypothesis testing (SHT) is central to these statistical principles and also aligns well with conventional scientific principles of evidence generation. Although there are challenges with SHT, good practitioners engaged in it do much more than just apply the mathematical theory behind it. As a particular example, lot of time in clinical trial designing is spent in addressing biases and designing trials prudently by minimizing the effect of such biases. SHT can benefit such an effort objectively. There is a need for Ayurveda researchers to engage deeply and mindfully about biases in study design in order to gain scientific validity and acceptability. The article highlights issues that arise in Ayurveda research, and discusses few ways of dealing with these issues using statistical principles.

  • Open Access

    A prospective comparative field study to evaluate the efficacy of a traditional plant-based malaria prophylaxis

    by Prakash Bangalore Nagendrappa, Pradeep Annamalai Annamalai, Muruli Naik, Vinay Mahajan, Frederick Gay, Ashwini Mathur, Ghosh Susanta, Padma Venkatasubramanian

    An unceasing threat of resistance of malarial parasites to available antimalarial drugs makes the development of new drugs imperative. Natural plant-based products are an alternative source for discovering new antimalarial drugs. To determine the prophylactic efficacy of a traditionally used plant-based drug on prevention of malaria in endemic villages of Odisha, India. A total of 267 healthy human volunteers of both sexes, aged 18-60 years were enrolled in Odisha, India, to receive either minimum 20 doses of aqueous extract of Traditional Plant-based Malaria Prophylactic drug 74, twice a week (experimental group), or no drug (control group) for 14 weeks. The primary criterion was the occurrence of malaria positive cases confirmed through expert microscopy during the study period. Analyses were by per-protocol (PP) and modified intention-to-treat (mITT). A significant (P < 0.01) reduction (64%) of malaria incidence was observed in the experimental group compared to control group, 12.3% and 26.6%, respectively, as PP analysis. However, the reduction was nonsignificant as per mITT analysis (P = 0.22). The experimental group showed a relative risk of 0.36 compared to control group. This preliminary study constitutes a potential "proof of concept" for the development of malaria prophylactic drug and provide a scientific basis for the use of traditional remedy as a malaria preventive by tribal populations in India.


  • Open Access

    Challenges in clinical research

    by Ashwini Mathur

    Perspect Clin Res, Official publication of Indian Society for Clinical Research,India


  • Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542

    by N. J. Laping, E. Grygielko, A. Mathur, S. Butter, J. Bomberger, C. Tweed, W. Martin, J. Fornwald, R. Lehr, J. Harling, et al.

    Transforming growth factor β1 (TGF-β1) is a potent fibrotic factor responsible for the synthesis of extracellular matrix. TGF-β1 acts through the TGF-β type I and type II receptors to activate intracellular mediators, such as Smad proteins, the p38 mitogen-activated protein kinase (MAPK), and the extracellular signal-regulated kinase pathway. We expressed the kinase domain of the TGF-β type I receptor [activin receptor-like kinase (ALK)5] and the substrate, Smad3, and determined that SB-431542 is a selective inhibitor of Smad3 phosphorylation with an IC50 of 94 nM. It inhibited TGF-β1–induced nuclear Smad3 localization. The p38 mitogen-activated protein kinase inhibitors SB-203580 and SB-202190 also inhibit phosphorylation of Smad3 by ALK5 with IC50values of 6 and 3 μM, respectively. This suggests that these p38 MAPK inhibitors must be used at concentrations of less than 10 μM to selectively address p38 MAPK mechanisms. However, the p38 MAPK inhibitor SB-242235 did not inhibit ALK5. To evaluate the relative contribution of Smad signaling and p38 MAPK signaling in TGF-β1–induced matrix production, the effect of SB-431542 was compared with that of SB-242235 in renal epithelial carcinoma A498 cells. All compounds inhibited TGF-β1–induced fibronectin (FN) mRNA, indicating that FN synthesis is mediated in part via the p38 MAPK pathway. In contrast, SB-431542, but not the selective p38 MAPK inhibitor SB-242235, inhibited TGF-β1–induced collagen Iα1 (col Iα1). These data indicate that some matrix markers that are stimulated by TGF-β1 are mediated via the p38 MAPK pathway (i.e., FN), whereas others seem to be activated via ALK5 signaling independent of the p38 MAPK pathway (i.e., col Iα1).


  • Top Cited Papers

    Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5)

    by James F. Callahan, Joelle L. Burgess, James A. Fornwald, Laramie M. Gaster, John D. Harling, Frank P. Harrington, Jag Heer, Chet Kwon, Ruth Lehr, A. Mathur, et al.

    Screening of our internal compound collection for inhibitors of the transforming growth factor β1 (TGF-β1) type I receptor (ALK5) identified several hits. Optimization of the dihydropyrroloimidazole hit 2 by introduction of a 2-pyridine and 3,4-methylenedioxyphenyl group gave 7, a selective ALK5 inhibitor. With this information, optimization of the triarylimidazole hit 8 gave the selective inhibitor 14, which inhibits TGF-β1-induced fibronectin mRNA formation while displaying no measurable cytotoxicity in the 48 h XTT assay.


  • Open Access

    Classification of Osteoporosis Based on Bone Mineral Densities

    by Ying Lu, Harry K. Genant, John Shepherd, Shoujun Zhao, Ashwini Mathur, Thomas P. Fuerst, Steven R. Cummings

    In this article we examine the role of bone mineral density (BMD) in the diagnosis of osteoporosis. Using information from 7671 women in the Study of Osteoporotic Fractures (SOF) with BMD measurements at the proximal femur, lumbar spine, forearm, and calcaneus, we examine three models with differing criteria for the diagnosis of osteoporosis. Model 1 is based on the World Health Organization (WHO) criteria using a T score of −2.5 relative to the manufacturers' young normative data aged 20-29 years, with modifications using information from the Third National Health and Nutrition Examination Survey (NHANES). Model 2 uses a T score of −1 relative to women aged 65 years at the baseline of the SOF population. Model 3 classifies women as osteoporotic if their estimated osteoporotic fracture risk (spine and/or hip) based on age and BMD is above 14.6%. We compare the agreement in osteoporosis classification according to the different BMD measurements for the three models. We also consider whether reporting additional BMD parameters at the femur or forearm improves risk assessment for osteoporotic fractures. We observe that using the WHO criteria with the manufacturers' normative data results in very inconsistent diagnoses. Only 25% of subjects are consistently diagnosed by all of the eight BMD variables. Such inconsistency is reduced by using a common elderly normative population as in model 2, in which case 50% of the subjects are consistently diagnosed as osteoporotic by all of the eight diagnostic methods. Risk-based diagnostic criteria as in model 3 improve consistency substantially to 68%. Combining the results of BMD assessments at more than one region of interest (ROI) from a single scan significantly increases prediction of hip and/or spine fracture risk and elevates the relative risk with increasing number of low BMD subregions. We conclude that standardization of normative data, perhaps referenced to an older population, may be necessary when applying T scores as diagnostic criteria in patient management. A risk-based osteoporosis classification does not depend on the manufacturers' reference data and may be more consistent and efficient for patient diagnosis.


  • Top Cited Papers

    Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response

    by Margaret J Leckie, Anneke Ten Brinke, Jamey Khan, Zuzana Diamant, Brian J O'Connor, Christine M Walls, Ashwini K Mathur, Hugh C Cowley, K Fan Chung, Ratko Djukanovic, et al.